Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Metastatic non-small cell lung cancer
0.020 GeneticVariation BEFREE In September 2018, dacomitinib received its first global approval, in the USA, for use in the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. 30506139 2018
Metastatic non-small cell lung cancer
0.020 GeneticVariation BEFREE It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutations. 24844234 2014